Efficacy and safety of mycophenolate mofetil in the treatment of moderate to severe Graves’ orbitopathy: a meta-analysis

References

• Bouzehouane N, Borson-Chazot F, Abeillon J, et al. Treatment of moderate to severe orbitopathy: current modalities and perspectives. Ann Endocrinol (Paris). 2021;82:92–98.
   PubMed Web of Science ®Google Scholar
• Łacheta D, Miśkiewicz P, Głuszko A, et al. Immunological aspects of Graves’ ophthalmopathy. Biomed Res Int. 2019;2019:7453260.
   PubMed Web of Science ®Google Scholar
• Huang Y, Fang S, Li D, et al. The involvement of T cell pathogenesis in thyroid-associated ophthalmopathy. Eye (Lond). 2019;33:176–182.
   PubMed Web of Science ®Google Scholar
• Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J. 2016; 5: 9–26.
   PubMed Web of Science ®Google Scholar
• Taylor PN, Zhang L, Lee RWJ, et al. New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. Nat Rev Endocrinol. 2020;16:104–116.
   PubMed Web of Science ®Google Scholar
• Lee ACH, Kahaly GJ. Novel approaches for immunosuppression in Graves’ hyperthyroidism and associated orbitopathy. Eur Thyroid J. 2020;9:17–30.
   PubMed Web of Science ®Google Scholar
• Calmet FH, Yarur AJ, Pukazhendhi G, et al. Endoscopic and histological features of mycophenolate mofetil colitis in patients after solid organ transplantation. Ann Gastroenterol. 2015;28:366–373.
   PubMedGoogle Scholar
• Ma X, Tang R, Luo M, et al. Efficacy of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis. Clin Rheumatol. 2021;40:3185–3193.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Huang J, Luo H, et al. Mycophenolate mofetil for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev. 2014; CD010242. 10.1002/14651858.CD010242.pub2.
   Web of Science ®Google Scholar
• Ye XZ, Bo XY, Hu XH, et al. Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves’ orbitopathy. Clin Endocrinol (Oxf). 2017;86:247–255.
   PubMed Web of Science ®Google Scholar
• Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves’ Orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol. 2021;185:G43–G67.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
   PubMed Web of Science ®Google Scholar
• Mourits MP, Prummel MF, Wiersinga WM, et al. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf). 1997;47:9–14.
   PubMed Web of Science ®Google Scholar
• Wang J, Wang YT, Shao JQ, et al. Clinical control study of mycophenolate in the treatment of thyroid associated ophthalmopathy. J Med Postgraduates. 2003;16:911–913.
   Google Scholar
• Zhang YS, Chen CB, Fu NX, et al. Comparison of mycophenolate and methylprednisolone in the treatment of infiltrating exophthalmos in Graves disease. Chongqing Med. 2011;40:3407–3409.
   Google Scholar
• Cui HH, Ye XZ, and Li YL, et al. Clinical observation of mycophenolate and other immunosuppressants in the treatment of thyroid associated ophthalmopathy. Chin J Clin(Elec Edn). 2013;7:11197–11200.
   Google Scholar
• Hu XH, Ye XZ, and Bo XY, et al. Clinical observation of mycophenolate mofetil in the treatment of active thyroid associated ophthalmopathy. J Med Postgraduates. 2015;28:268–271.
   Google Scholar
• Kahaly GJ, Riedl M, König J, et al. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves’ orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol. 2018;6:287–298.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
   PubMed Web of Science ®Google Scholar
• Higgins J, Thompson S, Deeks J, et al. Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J Health Serv Res Policy. 2002;7:51–61.
   PubMedGoogle Scholar
• Van Dyk HJ. Orbital Graves’ disease. A modification of the “NO SPECS” classification. Ophthalmology. 1981;88:479–483.
   PubMed Web of Science ®Google Scholar
• Zeng P, Fan SX, Li ZJ, et al. Evaluation of the Graves’ orbitopathy – specific quality of life questionnaire in the mainland Chinese population. J Ophthalmol. 2019;2019:7602419.
   PubMed Web of Science ®Google Scholar
• Khong JJ, McNab AA, Ebeling PR, et al. Pathogenesis of thyroid eye disease: review and update on molecular mechanisms. Br J Ophthalmol. 2016;100:142–150.
   PubMed Web of Science ®Google Scholar
• Zang S, Ponto KA, Kahaly GJ. Clinical review: intravenous glucocorticoids for Graves’ orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011;96:320–332.
   PubMed Web of Science ®Google Scholar
• Mele TS, Halloran PF. The use of mycophenolate mofetil in transplant recipients. Immunopharmacology. 2000;47:215–245.
   PubMed Web of Science ®Google Scholar
• Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol. 1993;11:S117–119.
   PubMed Web of Science ®Google Scholar
• Neurath MF, Wanitschke R, Peters M, et al. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn’s disease. Gut. 1999;44:625–628.
   PubMed Web of Science ®Google Scholar
• Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47:85–118.
   PubMed Web of Science ®Google Scholar
• Lee ACH, Riedl M, Frommer L, et al. Systemic safety analysis of mycophenolate in Graves’ orbitopathy. J Endocrinol Invest. 2020;43:767–777.
   PubMed Web of Science ®Google Scholar
• Rajabi MT, Rafizadeh SM, Mohammadi A, et al. Mycophenolate mofetil (CellCept®) in combination with low dose prednisolone in moderate to severe Graves’ orbitopathy. Front Med (Lausanne). 2022;9:788228.
   PubMed Web of Science ®Google Scholar
• Riedl M, Kuhn A, Krämer I, et al. Prospective, systematically recorded mycophenolate safety data in Graves’ orbitopathy. J Endocrinol Invest. 2016;39:687–694.
   PubMed Web of Science ®Google Scholar
• Quah Qin Xian N, Alnahrawy A, Akshikar R, et al. Real-world efficacy and safety of mycophenolate mofetil in active moderate-to-sight-threatening thyroid eye disease. Clin Ophthalmol. 2021;15:1921–1932.
   PubMed Web of Science ®Google Scholar
• Ye XZ, Huang SS, Liu J, et al. Efficacy and safety of mycophenolate mofetil in treatment of active moderate to severe thyroid-associated eye disease with glucocorticoid resistance. Chin J Endocrinol Metab. 2021;37:723–727.
   Google Scholar